UPSTREAM BIO, INC. (UPB) Spending and interest coverage
- R&D / revenue · 12 months: Value 4616.78%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 446.52%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 4616.78% | Research and development expense / revenue. Period ending 2026-06-30. $145.80M ÷ $3.16M × 100 ≈ 4616.78% |
| Stock-based compensation / revenue · 12 months | 446.52% | Share-based compensation / revenue. Period ending 2026-06-30. $14.10M ÷ $3.16M × 100 ≈ 446.52% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 145.80M USD | Research and Development Expense |
| Revenue | 3.16M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 14.10M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -169.98M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $145.80M | $3.16M | $14.10M | $-169.98M | (m) | 4616.78% | 446.52% | (m) | (m) |
| 2026-03-31 | $147.57M | $3.32M | $12.34M | $-171.96M | (m) | 4442.32% | 371.58% | (m) | (m) |
| 2025-12-31 | $136.81M | $2.85M | $10.33M | $-160.36M | (m) | 4793.48% | 362.02% | (m) | (m) |
| 2025-09-30 | $118.41M | $2.80M | $9.91M | $-140.51M | (m) | 4230.44% | 354.13% | (m) | (m) |
| 2025-06-30 | $100.87M | $2.72M | $9.18M | $-121.57M | (m) | 3704.30% | 337.16% | (m) | (m) |
| 2025-03-31 | $77.07M | $2.30M | $8.00M | $-94.76M | (m) | 3356.79% | 348.26% | (m) | (m) |
| 2024-12-31 | $62.97M | $2.37M | $6.00M | $-77.76M | (m) | 2656.79% | 253.33% | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $31.80M | $2.38M | $3.33M | $-40.11M | (m) | 1336.09% | 139.71% | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |